Lehman Brothers Global Healthcare Conference
|
|
- Osborne Harrell
- 6 years ago
- Views:
Transcription
1 Lehman Brothers Global Healthcare Conference Lawrence S. Olanoff - MD, Ph.D President and Chief Operating Officer March 20, 2007
2 Safe Harbor Except for the historical information contained herein, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of Because these statements involve a number of risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, challenges relating to intellectual property protection, the impact of competitive products and pricing, the timely development and launch of new products and the risk factors listed from time to time in the Company s SEC reports, including the Company s Annual Report on Form 10-K for the fiscal year ended March 31, 20.
3 Strategically Focused Supporting growth of in-market products while building the pipeline to deliver long-term earnings performance License promising new products from innovative companies worldwide at virtually every stage of development Conduct rigorous and aggressive scientific development programs for drug therapies that can make a unique contribution to the field of healthcare and the lives of patients Execute focused marketing and sales initiatives to firmly establish our products in the marketplace
4 Feb- Jun- Oct- Feb-07 Oct-05 Jun-05 Feb-05 2,700 2,600 2,500 2,400 2,300 2,200 2,100 Core Business Strength Monthly Total Prescriptions (TRx,000) Oct-04 Feb-05 Jun-05 Oct-05 Feb- Jun- Oct- Feb-07 Jun-04 Oct-04 1,200 1,100 1, Source: IMS Feb-07 Oct- Jun- Jun-04 Oct-04 Feb-05 Jun-05 Oct-05 Feb- Jun-04
5 Nov- Feb-07 14,500 14,000 13,500 13,000 12,500 12,000 11,500 11,000 SSRI Market Monthly TRx Volume 03 Δ 8.4% 04 Δ 2.8% 05 Δ -2.3% 03-Feb 03-MayAug-03 Nov-03 Feb-04May-04 Aug-04 Nov-04Feb-05 May-05 Aug-05Nov-05 Feb- May-Aug- SSRI TRx 3 Mo Av Avg. Δ 6.4%
6 SRI Market: Category Leadership in Detailing Detailing Investment ($,000) 14,000 12,000 Three Key Players 10,000 8,000 6,000 4,000 2,000 0 Jan- 05 Mar- 05 May- 05 Jul- 05 Sep- 05 Nov- 05 Jan- Mar- May- Jul- Sep- Nov- Jan- 07 LEXAPRO PAXIL+CR ZOLOFT CYMBALTA EFFEXOR/XR Source: IMS Integrated Promotional Services
7 Alzheimer s Market Growing Prevalence of Combination Therapy Network: Neurologist Mild Moderate Severe Namenda + AChE Inhibitor Combo Therapy Namenda Monotherapy AChE Inhibitor Monotherapy 16% 16% 16% 20% 18% 6% 7% 7% 4% 9% 11% 3% 41% 49% 44% 44% 47% 49% 62% 50% 73% 69% 62% 10% 8% 9% 9% 12% 9% 87% 12% 77% 77% 77% 76% 73% 10% 14% 2% 50% 42% 5% 10% 42% 42% 48% 47% 38% 30% 28% 24% 21% 21% n= % Mar- Apr- May- Jun- Jul- Aug- Mar- Apr- May- Jun- Jul- Aug- Mar- Apr- May- Jun- Jul- Aug-
8 Aug- Nov- Feb-07 Monthly Market Share 35.00% 30.00% 25.00% 20.00% 15.00% 10.00% 5.00% 0.00% Feb-04 May-04 Aug-04 Nov-04 Feb-05 May-05 Aug-05 Nov-05 Feb- May- NRx Share TRx Share 32.9% N 32.4% T
9 Monthly NRx Share ARB + Combo Market 40% 35% 30% 25% 20% 15% 10% 5% 0% 7 th entry Feb- Jun Oct- 03 Feb- 04 Jun- 04 Oct- 04 Feb- 05 Jun- 05 Oct- 05 Feb- Jun- BENICAR + HCT COZAAR + HYZAAR DIOVAN+DIOVAN HCT Oct- Feb % 3 rd in market share AVAPRO+AVALIDE ATACAND+ATACAND HCT MICARDIS+MICARDIS HCT Benicar is a registered trademark of Sankyo Pharma
10 Competitive Sales Force Ranked 14 th by Salesforce Size in US Source: Verispan 1 st Productivity 2 nd Forest 3 rd 4 th 5 th 2 nd Forest 1 st Sales Call Quality 2 nd 3 rd 4 th 5 th Forest 2 nd Forest Sensitivity to Time Constraints - GP 1 st 2 nd 3 rd 4 th 5 th Forest 2 nd Forest Unbiased Product Comparisons - GP 1 st 2 nd 3 rd 4 th Forest 4 th 5 th Forest
11 Ability to Compete Against Large Pharma Prozac (Eli Lilly) Zoloft (Pfizer) Paxil (Glaxo-SmithKline) Effexor (Wyeth) Cymbalta (Eli Lilly) Aricept (Pfizer) Exelon (Novartis) Razadyne (Johnson & Johnson) Diovan (Novartis) Cozaar (Merck) Avapro (Bristol-Myers Squibb)
12 Looking Forward
13 Licensing Criteria Late Phase Development Projects (Phase II POC and after) Opportunistic Individual Product Licenses/Acquisitions Co-Development and/or Co-Marketing Arrangements Follow-on Products from Established Partners Early Phase or Preclinical Projects (Pre-Phase II Results) Specific Therapeutic Targets of Interest Joint Venture or Portfolio Licensing Agreements Forest Development or Shared Development Discovery Projects/Target Identification (No Lead Candidate at Initiation)
14 Partner of Choice Products with potential peak sales of less than $1 Billion are attractive to Forest. Do not compete with our ex-us partners in their home markets, comfortable with both US-only or global license distribution agreements. We do not have a traditional drug discovery component that generates competitive drug candidates to partner projects. Partners can see Forest as their mirror image in terms of structure and size. Senior Management, including CEO, are involved in the deal agreement and in actively managing the project post agreement. No history of acquiring partners, whereas we frequently have the opportunity to review and sometimes license newly offered products from established partners.
15 The Forest Pipeline: Pre-Clinical/Phase I The Forest Pipeline Phase II Phase III NDA/sNDA mglur-5 for various CNS conditions ME1036 Broad spectrum carbapenem RGH-188 for schizophrenia and bipolar mania RGH-896 for chronic pain and other CNS conditions milnacipran for fibromyalgia ceftaroline for CAP, csssi Aclidinium for COPD Namenda QD for Alzheimer s disease nebivolol for hypertension Metabolic Target Lead project Obesity/Diabetes GRC-3886 (oglemilast) for COPD and asthma nebivolol- CHF neramexane for Alzheimer s disease desmoteplase for acute stroke Lexapro Pediatric indication
16 Pipeline: Key Initiatives Nebivolol Licensed January 11, 20 from Mylan Laboratories Novel beta blocker for hypertension Most highly selective beta blocker Has favorable differentiating characteristics, based on the Phase III studies Mylan Received FDA Approvable Letter May 31, 2005 Expect to submit response to Approvable Letter around the end of Fiscal Year 2007 Plans to submit a separate NDA for the treatment of congestive heart failure
17 Pipeline: Key Initiatives Milnacipran Dual Serotonin Norepinephrine Reuptake Inhibitor investigated for fibromyalgia (Cypress) Encouraging results from first Phase III Study: n=888 Predefined Primary Composite Endpoint which includes Pain and Patient Global Assessment yield p-value=0.058 LOCF analysis, Dropouts analyzed by BOCF yielded p-value= Enrollment in second Phase III study increased to 1,200 patients from 800 patients Topline Results to be reported during 2Q-calendar year Three-month endpoint. Ongoing discussions with FDA regarding analysis plan for second study Third Phase III Study enrolling targeted at 800 patients Significant market opportunity
18 Pipeline: Key Initiatives Ceftaroline Lead compound from acquisition of Cerexa, Inc. completed in January 2007 Broad-spectrum fifth generation Cephalosporin entering Phase III trials for csssi and CAP in (Active against MRSA) Injectable antibiotic for future sale by FRX Hospital Salesforce Hospital Infections kill 90,000/yr: excess costs of $4.5B (CDC est. WSJ 12/26/). Experienced antibiotic development team from Cerexa
19 Upcoming Clinical Data Topline Results Milnacipran Second Phase III Study Desmoteplase DIAS 2 Memantine Phase III AD - MR RGH-188 Phase II Bipolar Mania Ceftaroline CSSSI- Phase III (2 Studies) RGH-188 Phase II Schizophrenia Lexapro Phase III Pediatric/Adolescent Depression Milnacipran Third Phase III Study Aclidinium - Phase III COPD (2 Studies)
20 Corporate Overview Lawrence S. Olanoff - MD, Ph.D President and Chief Operating Officer
January 2019 Investor Presentation NASDAQ: ATRS
January 2019 Investor Presentation NASDAQ: ATRS Safe Harbor Statement This presentation contains forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation
More informationBUSINESS UPDATE CALL. September 7, 2017
BUSINESS UPDATE CALL September 7, 2017 INTRODUCTION Gem Hopkins VP, Investor Relations & Corporate Communications SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation
More informationCatching the Bug for Novel Antibiotics: Roundtable Conference
Leerink Swann & Company Catching the Bug for Novel Antibiotics: Roundtable Conference March 6, 2007 Nebojsa Janjic Chief Scientific Officer We are providing this information as of February 12, 2007 and
More informationCowen and Company 34 th Annual Health Care Conference
Cowen and Company 34 th Annual Health Care Conference March 3, 2014 Forward-Looking Statement Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements
More informationJapan: Subgroup Report
Global Edge Consultants Japan: Subgroup Report Lisa A Bartha Sonya Kinch-Monyem Lindsay B Yacavone AMBA606, Section 9011 Professor Jane Ross August 6, 2006 Japan: Subgroup report 2 Table of Contents Table
More informationImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update
August 2, 2013 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update Kadcyla sales off to strong start. Decision
More informationPromotion and Development Collaborations Between Established Players
Promotion and Development Collaborations Between Established Players Randall B. Sunberg Pharma and Biotech In-Licensing, Co-Development and Co-Promotion Agreements October 21-22, 2002 1 www.morganlewis.com
More informationTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
February 27, 2017 Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update Key Program Milestones Anticipated in 2017 and 2018 DUBLIN, Feb. 27,
More informationFORWARD LOOKING STATEMENTS
Jefferies 2014 Healthcare Conference November 19, 2014 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. Any statements contained herein which do not describe historical
More informationDatamonitor Healthcare Pharma intelligence informa Datamonitor Healthcare Content Calendar
Datamonitor Healthcare 2017 Datamonitor Healthcare Content Calendar 2017 Content Calendar Published February 2017 Datamonitor Healthcare provides up-to-date insights and analysis that you can trust. Disease
More informationThe Growth Strategy of Shionogi. September, 2011
The Growth Strategy of Shionogi September, 2011 Forward-Looking Statements This presentation contains forward-looking statements. These statements are based on expectations in light of the information
More informationMedical breakthroughs have always driven our business
1 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates,
More informationNASDAQ: ATRS. September 2016
NASDAQ: ATRS September 2016 1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act
More informationAdam Schechter President, U.S. Human Health
Adam Schechter President, U.S. Human Health Goldman Sachs 28th Annual Global Healthcare Conference June 13, 2007 Forward-Looking Statement This presentation contains "forward-looking statements" as that
More informationInvestor Presentation June 2006
Investor Presentation June 2006 Safe Harbor This presentation contains certain forward-looking statements. These statements are based on the current estimates and assumptions of the management of Adams
More informationTOKYO, JAPAN AND SOUTH SAN FRANCISCO,
Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe TOKYO, JAPAN AND SOUTH SAN FRANCISCO, CA/October
More informationSecond Mid-term Business Plan - FY2010 to FY2014 -
0 Second Mid-term Business Plan - FY2010 to FY2014 - - Creation and transformation toward a new stage of globalization - Dainippon Sumitomo Pharma Co., Ltd. Masayo Tada, President February 16, 2010 1 Agenda
More informationApricus Biosciences, Inc. (NASDAQ:APRI) Corporate Presentation BIO CEO & Investor Conference New York City. Tuesday February 12, 2013
Apricus Biosciences, Inc. (NASDAQ:APRI) Corporate Presentation BIO CEO & Investor Conference New York City Tuesday February 12, 2013 1 Safe Harbor Statement Statements under the Private Securities Litigation
More informationBRINGING SCIENCE AND TECHNOLOGY TO MAKE BETTER PRODUCTS FOR A HEALTHIER LIFE. April 11, 2019
BRINGING SCIENCE AND TECHNOLOGY TO MAKE BETTER PRODUCTS FOR A HEALTHIER LIFE April 11, 2019 SAFE HARBOR S T A T E M E N T Statements under the Private Securities Litigation Reform Act, as amended: With
More informationCORPORATE PRESENTATION January 2019
CORPORATE PRESENTATION January 2019 1 DISCLAIMER This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ( Outlook Therapeutics or the Company ) based on management s current
More informationActing Deputy Commissioner for Operations, U.S. Food and Drug Administration
Available on FDA website at: http://www.fda.gov/newsevents/testimony/ucm113266.htm Pediatric Clinical Trials for Anti-depressant Drug Products Statement of Janet Woodcock, M.D. Acting Deputy Commissioner
More informationTELECONFERENCE Q November 2014
TELECONFERENCE Q3 2014 5 November 2014 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationSanten Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Akira Kurokawa President & CEO August 2, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 External
More informationAVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update
AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. November 4, 2016 AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter
More informationJefferies 2016 Healthcare Conference. June 7, 2016
Jefferies 2016 Healthcare Conference June 7, 2016 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management
More informationAltraGen Senior management leadership offsite Day 1: Introduction
AltraGen Senior management leadership offsite Day 1: Introduction 0 AltraGen outsells its competitors because it offers what no one else can a complete product portfolio in pharmaceuticals Why we have
More informationSpectrum Pharmaceuticals Jefferies 2015 Global Healthcare Conference
Spectrum Pharmaceuticals Jefferies 2015 Global Healthcare Conference June 3 rd, 2015 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements
More informationAdam Schechter President, Global Human Health. Merck & Co., Inc. Cowen 2015 Healthcare Conference. March 3, 2015
Adam Schechter President, Global Human Health Merck & Co., Inc. Cowen 2015 Healthcare Conference March 3, 2015 Forward-Looking Statement This communication includes forward-looking statements within the
More informationPfenex Inc. San Diego, CA NYSE MKT: PFNX. Updated July 2017
Pfenex Inc. San Diego, CA NYSE MKT: PFNX Updated July 2017 Safe Harbor Statement This presentation (the Presentation ) includes forward looking statements within the meaning of the Private Securities Litigation
More informationNASDAQ: ATRS. Investor Presentation January 2017
NASDAQ: ATRS Investor Presentation January 2017 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationHow Competitive Marketing Expenditures Influence the Growth of Markets
How Competitive Marketing Expenditures Influence the Growth of Markets Yi Xiang, David Soberman and Hubert Gatignon ECMI-AMA-EMAC Symposium, Rotterdam, May 2014 1 Research Questions How competitive marketing
More informationHAI event March 2009
HAI event March 29 Thanks and an apology A Project Moving a Big Dot TM 10 Scottish Patient Safety Alliance (SPSA) Driver Diagram Improve Safety of Healthcare Services in Scotland Primary Drivers Scottish
More informationInnovative therapies for Alzheimer s disease
WHITE PAPER IMS DISEASE INSIGHTS Innovative therapies for Alzheimer s disease New treatments will drive significant market value growth over the next ten years Author: Peter Alfinito, Ph.D., lead AnAlyst,
More informationFuriex Pharmaceuticals
Furiex Pharmaceuticals NASDAQ: FURX June Almenoff MD, PhD President & Chief Medical Officer Bio CEO & Investor Conference February 2011 Forward-Looking Statements This presentation includes forward-looking
More informationMarket Analysis & Segmentation. Gary Phillips CEO Bioshares 29 July 2016
Market Analysis & Segmentation Gary Phillips CEO Bioshares 29 July 2016 1 Forward looking statement This document contains forward looking statements, including statements concerning Pharmaxis future financial
More informationCorporate Presentation January 2019
Corporate Presentation January 2019 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management s current expectations
More informationRoche Committed to Innovation. Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008
Roche Committed to Innovation Sal. Oppenheim European Healthcare Investors Conference Frankfurt, September 2, 2008 This presentation contains certain forward-looking statements. These forward-looking statements
More informationPfenex Inc. San Diego, CA NYSE MKT: PFNX
Pfenex Inc. San Diego, CA NYSE MKT: PFNX Safe Harbor Statement This presentation (the Presentation ) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationOverview: The future of medicine is personalised. Severin Schwan, CEO
Overview: The future of medicine is personalised Severin Schwan, CEO This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes,
More informationEconomic Incentives for Genetic and Genomic Strategies: Stratified Medicines
Economic Incentives for Genetic and Genomic Strategies: Stratified Medicines 1 P R E S E N T A T I O N A T I O M W O R K S H O P 2 1 M A R C H, 2 0 1 2 M A R K T R U S H E I M V I S I T I N G S C I E N
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationFirst Quarter 2018 Financial Results & Update
First Quarter 2018 Financial Results & Update April 26, 2018 Forward-Looking Statements and Non-GAAP Financial Information 2 Certain statements set forth in this presentation constitute forward-looking
More informationOryzon Genomics SA ORY.SM MADRID Buy
Jotin Marango, M.D., Ph.D., (646) 616-2780 jmarango@roth.com Sales (800) 933-6830, Trading (800) 933-6820 COMPANY NOTE EQUITY RESEARCH November 13, 2018 Healthcare: Biotechnology Oryzon Genomics SA ORY.SM
More informationImmune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 1, 2017 Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 01,
More informationSosei Business Update and Revised Financial Forecast Following Acquisition of Arakis
Sosei Business Update and Revised Financial Forecast Following Acquisition of Arakis Tokyo, Japan 16 December 2005: Sosei Co. Ltd ("Sosei" - 4565, Tokyo Stock Exchange MOTHERS index), a leading Japanese
More informationVISION & STRATEGY FIC LIC. Interview with the President
VISION & STRATEGY Interview with the President A conversation with Isao Teshirogi, President and CEO about the Shionogi Growth Strategy 2020 (SGS2020) VISION & STRATEGY SGS2020 Growth Strategies Under
More informationPersonalized Medicine: The Changing Landscape of Health Care
Personalized Medicine: The Changing Landscape of Health Care The 2 nd Biomarker Meeting in Personalized Reproductive Medicine Valencia, Spain 11 April, 2014 Edward Abrahams, Ph.D. President Personalized
More informationJohan Christenson MD; PhD Partner Farmasidagene 2014 Oslo
Johan Christenson MD; PhD Partner Farmasidagene 2014 Oslo 1 HealthCap Focuses on Breakthrough Therapeutics Significant resource base Partners with profound sector experience Six MD PhD s Extensive network
More informationQIAGEN Sample & Assay Technologies From Discovery to Patient
QIAGEN From Discovery to Patient New York, February 14 QIAGEN 2008 Analyst & Investor Day Peer Schatz, CEO -7- Forward Looking Statements Safe Harbor Statement: Certain of the statements contained in this
More informationUBS 2007 Global Life Sciences Conference. September 24, 2007
UBS 2007 Global Life Sciences Conference September 24, 2007 Safe Harbor This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section
More informationElectric Forward Market Report
Mar-01 Mar-02 Jun-02 Sep-02 Dec-02 Mar-03 Jun-03 Sep-03 Dec-03 Mar-04 Jun-04 Sep-04 Dec-04 Mar-05 May-05 Aug-05 Nov-05 Feb-06 Jun-06 Sep-06 Dec-06 Mar-07 Jun-07 Sep-07 Dec-07 Apr-08 Jun-08 Sep-08 Dec-08
More informationImportant notice. 139 th Ordinary general meeting of shareholders. Christophe Weber President & Chief Executive Officer
139 th Ordinary general meeting of shareholders Christophe Weber President & Chief Executive Officer June 26, 2015 Important notice Forward-Looking Statements This presentation contains forward-looking
More informationINVESTOR PRESENTATION. June 2018
INVESTOR PRESENTATION June 2018 Safe Harbor Statement This presentation contains forward looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform
More informationInvestor Presentation. October 2018
Investor Presentation October 2018 Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the Private Securities Litigation
More informationFourth Quarter and Full Year Financial and Operational Results Conference Call March 21, 2018
Fourth Quarter and Full Year 2017 Financial and Operational Results Conference Call March 21, 2018 Copyright Akari Therapeutics, Plc - 2018 Disclaimers Certain statements in this presentation constitute
More informationAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 1, 2017 Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs Robust balance sheet to support global expansion of ACH-4471 clinical development program
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationModels of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics
Models of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics Safety Evaluation is Not Completed at Approval Phase 3 programs evaluate efficacy and general safety/tolerability
More informationPain Therapeutics, Inc. Pain Therapeutics Announces Update on Drug Portfolio
For More Information Contact: Peter S. Roddy Vice President and Chief Financial Officer Pain Therapeutics, Inc. proddy@paintrials.com 512 501 2450 FOR IMMEDIATE RELEASE Pain Therapeutics Announces Update
More informationEagle Pharmaceuticals NASDAQ: EGRX
Eagle Pharmaceuticals NASDAQ: EGRX Scott Tarriff, CEO David Riggs, CFO June 2015 Forward Looking Statements This presentation contains certain forward-looking information about Eagle Pharmaceuticals that
More informationNew Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation
New Ways to Source Innovation in the Healthcare Industry In-licensing needs Oncology of Janssen/Johnson & Johnson Innovation Dr. Klaus Suwelack Johnson & Johnson Innovation, Janssen-Cilag Germany, Neuss
More informationnovel drug molecule for the treatment of Chronic Pain
novel drug molecule for the treatment of Chronic Pain Pandemic Problem Chronic Pain need adequate non opioid novel drug molecule to treat Chronic pain still a pandemic in the 21st century Chronic pain
More informationSYNTHETIC BIOLOGICS, INC.
SYNTHETIC BIOLOGICS, INC. FORM DEFA14A (Additional Proxy Soliciting Materials (definitive)) Filed 05/12/14 Address 155 GIBBS STREET SUITE 412 ROCKVILLE, MD 20850 Telephone (734) 332-7800 CIK 0000894158
More informationRoche: adapting to the changing environment. Severin Schwan, CEO Roche Group London, 15 September 2010
Roche: adapting to the changing environment Severin Schwan, CEO Roche Group London, 15 September 2010 This presentation contains certain forward-looking statements. These forward-looking statements may
More informationSynthetic Biologics Reports Year End 2012 Financial Results
April 16, 2013 Synthetic Biologics Reports Year End 2012 Financial Results -- Strengthening Infectious Disease Portfolio to Include C. difficile, Pertussis and Acinetobacter Targets -- ROCKVILLE, Md.,
More informationStrategic trends facing the pharmaceutical industry and their implications for marketing skills development Received: 4th September, 2002
Strategic trends facing the pharmaceutical industry and their implications for marketing skills development Received: 4th September, 2002 Gill Butler has worked in the pharmaceutical industry for 21 years,
More informationRoche in Australia Innovation Leader
Roche in Australia Innovation Leader About Roche Innovation: it s in our DNA 7,000,874 hours of work 6,587 experiments 423 researchers 1 drug For nearly 120 years, Roche has been committed to improving
More informationParameters of Development - Drug Delivery Enabled/Enhanced Products (DDEP ) A Review (Chapter 7)
CHAPTER 7 FDA DRUG APPROVALS, 2000-2010 Introduction This chapter reviews drug delivery enabled/enhanced product approvals by the FDA over the period 2000-2010. This is a simple analysis that provides
More information1 st Quarter 2007 Earnings. April 19, 2007
1 st Quarter 2007 Earnings April 19, 2007 Forward-Looking Statement The statements in this presentation that are not historical facts are forward-looking statements based on current expectations of future
More informationWITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT
WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges
More informationUniversity of Michigan Eco-Driving Index (EDI) Latest data: August 2017
University of Michigan Eco-Driving Index () http://www.ecodrivingindex.org Latest data: August 2017 Developed and issued monthly by Michael Sivak and Brandon Schoettle Sustainable Worldwide Transportation
More informationJEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 4, 2015 VINCENT J. ANGOTTI, CHIEF OPERATING OFFICER
JEFFERIES 2015 GLOBAL HEALTHCARE CONFERENCE JUNE 4, 2015 VINCENT J. ANGOTTI, CHIEF OPERATING OFFICER COPYRIGHT 2015 XENOPORT, INC. ALL RIGHTS RESERVED. SAFE HARBOR LANGUAGE These slides and the accompanying
More informationFor personal use only
For personal use only Eli Lilly, Bio-Medicines Rob Brown Chief Marketing Officer, Eli Lilly and Company Senior Vice President, Eli Lilly Bio-Medicines Report to Acrux Investment Community Eli Lilly and
More informationValuing and Licensing Intellectual Property. Richard Williams
c Healthcare Valuing and Licensing Intellectual Property Richard Williams 9 May 2001 Agenda Exploitation of intellectual property The licence route- why and when? Choosing a partner Practical considerations
More information35 th Annual J.P. Morgan Healthcare Conference. Gwan Sun Lee. President & CEO
35 th Annual J.P. Morgan Healthcare Conference Gwan Sun Lee President & CEO This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses
More informationInvestor Presentation: Phase II Data for LCP Tacro. March 3, 2008
Investor Presentation: Phase II Data for LCP Tacro March 3, 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may,
More informationVenture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program. A FasterCures Webinar June 19, 2013
Venture Philanthropy Models: The Leukemia & Lymphoma Society's Therapy Acceleration Program A FasterCures Webinar June 19, 2013 What is FasterCures? Founded in 2003, our mission is to save lives by saving
More information2016 Summary Financial Results
ARCA BIOPHARMA ANNOUNCES FISCAL YEAR 2016 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE -------------------------------------------------------------------------------------------------- GENETIC-AF Phase
More informationSmall-Cap Research OUTLOOK. V.DMA: Zacks Company Report
Small-Cap Research November 27, 2017 Grant Zeng, CFA 312-265-9421 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 DiaMedica Therapeutics (V.DMA-TSX, DMCAF-OTC) V.DMA: Zacks Company
More informationAbout the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
More informationPharmaceutical Innovation at a Crossroads
Pharmaceutical Innovation at a Crossroads The New Face of Pharma R&D Kenneth I Kaitin, Ph.D. Director and Research Professor Tufts Center for the Study of Drug Development Global Clinical Supply Group
More informationAMGEN AND CENTOCOR ORTHO BIOTECH PRODUCTS FINALIZE ESA RISK EVALUATION AND MITIGATION STRATEGY (REMS) WITH FDA
News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone (805) 447-1000 Fax (805) 499-3507 www.amgen.com AMGEN AND CENTOCOR ORTHO BIOTECH PRODUCTS FINALIZE ESA RISK EVALUATION AND MITIGATION
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationGLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS
GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS BIO021E May 2016 Shalini Shahani Dewan Project Analyst ISBN: 1-62296-288-5 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationINVESTOR PRESENTATION 2018
INVESTOR PRESENTATION 2018 IMMUNOPRECISE ANTIBODIES, LTD. UNIT 3204-4464 MARKHAM STREET VICTORIA, BRITISH COLUMBIA V8Z 7X8, CANADA IMMUNOPRECISE.COM 1 Disclosures DISCLAIMER This presentation is not, and
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Giovanni Caforio Chief Operating Officer January 13, 2015 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects
More informationAllergan to Acquire Naurex
NEWS RELEASE CONTACTS: ALLERGAN: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 NAUREX: Canale Communications Pam Lord pam@canalecomm.com 619-849-6003 Naurex Inc. Ashish Khanna
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationtrial. Key trial data points:
February 23, 2015 ADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference RAMSEY, N.J., Feb. 23, 2015
More informationGlobal Pharmaceutical Industry Profile 2012
2012 1. Global Pharmaceuticals Market 1.1 Pharmaceutical Sector (Market) Performance The global pharmaceutical market has shown steady growth throughout the years. In particular, the market size of the
More informationARIKAYCE U.S. FDA Approval
S E P T E M B E R 2 8, 2 0 1 8 ARIKAYCE U.S. FDA Approval Forward Looking Statements This presentation contains forward-looking statements. "Forward-looking statements," as that term is defined in the
More informationArthur P. Bedrosian, Chief Executive Officer Brian Kearns, Chief Financial Officer. Investor Presentation February 2009
Arthur P. Bedrosian, Chief Executive Officer Brian Kearns, Chief Financial Officer Investor Presentation February 2009 Safe Harbor Statement Except for historical facts, the statements in this presentation,
More informationThe Current Status at Shionogi
Nomura Investment Forum 2008 The Current Status at Shionogi December 2, 2008 Isao Teshirogi, Ph.D. President and Representative Director Forward-Looking Statements This presentation contains forward-looking
More informationFIGURE 2 GLOBAL MARKET FORECAST FOR ALS THERAPEUTICS, ($ MILLIONS) THE U.S. MARKETS (CONTINUED) ALS: BACKGROUND INFORMATION...
INTRODUCTION... xix STUDY GOALS AND OBJECTIVES... xix REASONS FOR DOING THE STUDY... xix AUDIENCE FOR THE REPORT... xx SCOPE AND FORMAT... xx METHODOLOGY AND INFORMATION SOURCES... xxi ABOUT THE AUTHOR...
More informationImportant Update on EpiPen (epinephrine injection, USP) 0.3 mg Auto-Injectors from Mylan and Pfizer
August 21, 2018 Important Update on EpiPen (epinephrine injection, USP) 0.3 mg Auto-Injectors from Mylan and Pfizer Extended Expiration Dates for Select Lots of EpiPen 0.3 mg Auto- Injectors and its Authorized
More informationCompany Report Daring to be different
Company Report 2010 Daring to be different Daring to be different Galapagos has continued to follow its own unique path and is now a leading international biotechnology company. In our 2010 report, we
More informationModerna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities
Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 26 Strategic Priorities First Phase I study underway in Europe for mrna 44; IND for second program,
More information